Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study
- 4 June 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 41 (22), 2058-2066
- https://doi.org/10.1093/eurheartj/ehaa433
Abstract
Aims: It remains unknown whether the treatment of hypertension influences the mortality of patients diagnosed with coronavirus disease 2019 (COVID-19). Methods and results: This is a retrospective observational study of all patients admitted with COVID-19 to Huo Shen Shan Hospital. The hospital was dedicated solely to the treatment of COVID-19 in Wuhan, China. Hypertension and the treatments were stratified according to the medical history or medications administrated prior to the infection. Among 2877 hospitalized patients, 29.5% (850/2877) had a history of hypertension. After adjustment for confounders, patients with hypertension had a two-fold increase in the relative risk of mortality as compared with patients without hypertension [4.0% vs. 1.1%, adjusted hazard ratio (HR) 2.12, 95% confidence interval (CI) 1.17–3.82, P = 0.013]. Patients with a history of hypertension but without antihypertensive treatment (n = 140) were associated with a significantly higher risk of mortality compared with those with antihypertensive treatments (n = 730) (7.9% vs. 3.2%, adjusted HR 2.17, 95% CI 1.03–4.57, P = 0.041). The mortality rates were similar between the renin–angiotensin–aldosterone system (RAAS) inhibitor (4/183) and non-RAAS inhibitor (19/527) cohorts (2.2% vs. 3.6%, adjusted HR 0.85, 95% CI 0.28–2.58, P = 0.774). However, in a study-level meta-analysis of four studies, the result showed that patients with RAAS inhibitor use tend to have a lower risk of mortality (relative risk 0.65, 95% CI 0.45–0.94, P = 0.20). Conclusion: While hypertension and the discontinuation of antihypertensive treatment are suspected to be related to increased risk of mortality, in this retrospective observational analysis, we did not detect any harm of RAAS inhibitors in patients infected with COVID-19. However, the results should be considered as exploratory and interpreted cautiously.Keywords
This publication has 29 references indexed in Scilit:
- 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of HypertensionJournal of Hypertension, 2018
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionEuropean Heart Journal, 2018
- Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltrationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2018
- An introduction to multiplicity issues in clinical trials: the what, why, when and howInternational Journal of Epidemiology, 2016
- Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitorsAmino Acids, 2014
- Angiotensin II Mediates Angiotensin Converting Enzyme Type 2 Internalization and Degradation Through an Angiotensin II Type I Receptor–Dependent MechanismHypertension, 2014
- A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injuryNature Medicine, 2005
- Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2Circulation, 2005
- Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolismBiochemical Journal, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004